Related Experiment Video

Updated: Sep 14, 2026

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled

M R Farlow1, P A Cyrus

  • 1Indiana University School of Medicine, Indianapolis, Ind. 46202-5111, USA. MFARLOW@IUPUI.EDU

Dementia and Geriatric Cognitive Disorders
|June 27, 2000
PubMed

Insights

Metrifonate effectively treats mild to moderate Alzheimer's disease (AD), significantly improving cognition, behavior, and daily living functions. This cholinesterase inhibitor offers a comprehensive treatment option for AD patients.

Area of Science:

  • Neurology
  • Pharmacology
  • Geriatrics

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and behavioral disturbances.
  • Current treatments for AD primarily focus on symptomatic relief, with limited options for addressing the multifaceted nature of the disease.

Purpose of the Study:

  • To evaluate the efficacy of metrifonate, a cholinesterase inhibitor, in treating patients with mild to moderate Alzheimer's disease.
  • To assess the impact of metrifonate on cognitive function, behavioral symptoms, and activities of daily living.

Main Methods:

  • A retrospective analysis pooling data from four Food and Drug Administration-compliant studies.
  • Intent-to-treat analyses included patients receiving placebo (n=550), metrifonate 30-60 mg (n=769), or metrifonate 60/80 mg (n=197).
  • Efficacy was measured using standardized scales including ADAS-Cog, MMSE, Neuropsychiatric Inventory, ADAS-Noncognitive, and Disability Assessment for Dementia.

Main Results:

  • Metrifonate 60/80 mg significantly improved cognitive abilities (ADAS-Cog, MMSE) compared to placebo (p=0.0001).
  • The treatment also significantly reduced psychiatric and behavioral disturbances (Neuropsychiatric Inventory, p=0.039) and improved daily living performance (Disability Assessment for Dementia, p=0.0002).
  • Effects were dose-dependent, with the higher dose showing significant improvements in cognition, behavior, daily function, and global status.

Conclusions:

  • Metrifonate is the first cholinesterase inhibitor to demonstrate significant improvements in cognition, behavior, and functional status in mild to moderate Alzheimer's disease under prospective, placebo-controlled conditions.
  • The findings support metrifonate as an effective therapeutic agent for managing the diverse symptoms of Alzheimer's disease.
  • The dose-related efficacy suggests an optimized treatment regimen can be established for metrifonate in AD patients.

More Related Videos

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)06:41

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Published on: January 10, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-145105:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...